Online citations, reference lists, and bibliographies.
← Back to Search

Ipilimumab And Nivolumab In The Treatment Of Recurrent Malignant Pleural Mesothelioma (INITIATE): Results Of A Prospective, Single-arm, Phase 2 Trial.

M. Disselhorst, J. Quispel-Janssen, F. Lalezari, K. Monkhorst, J. F. de Vries, V. van der Noort, E. Harms, S. Burgers, P. Baas
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Single-drug checkpoint inhibition has shown efficacy in patients with recurrent malignant pleural mesothelioma. Here, we assessed the safety and efficacy of the combination of nivolumab, an anti-programmed cell death 1 antibody, plus ipilimumab, an anti-cytotoxic T-lymphocyte protein 4 antibody, in patients with previously treated and relapsed malignant pleural mesothelioma. METHODS INITIATE was a prospective single-centre, single arm, phase 2 trial. Patients with malignant pleural mesothelioma who progressed after at least one line of platinum-containing chemotherapy were enrolled. Key eligibility criteria were measurable disease according to the modified Response Evaluation Criteria in Solid Tumours for mesotheliomas, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received intravenous nivolumab (240 mg every 2 weeks) plus intravenous ipilimumab (1 mg/kg every 6 weeks up to four times). Treatment was continued for up to 2 years or until confirmed progression or unacceptable toxicity. The primary endpoint was disease control at 12 weeks. All patients who received at least one dose of therapy were included in safety analysis and all patients who received one dose of therapy and at least one radiological assessment were included in the primary analysis. This trial is registered at ClinicalTrials.gov, number NCT03048474. FINDINGS Between Oct 5, 2016, and Aug 3, 2017, 38 patients were enrolled in the study, of which two patients were excluded because they were not eligible for a biopsy. Of 36 eligible patients, one deteriorated before the start of the study so was not included in any analyses and one withdrew consent after one treatment cycle before radiological assessment so was included in the safety population only. 34 patients were evaluable for response assessment at 12 weeks. Of these, ten (29%) patients had a partial response and 13 (38%) patients had stable disease; thus, disease control was achieved by 23 (68%, 95% CI 50-83) of 34 patients. Treatment-related adverse events were reported in 33 (94%) patients. The most common adverse events were infusion-related reactions, skin disorders, and fatigue. Grade 3 treatment-related adverse events were reported in 12 (34%) of 35 patients. INTERPRETATION In this single-centre phase 2 trial, the combination of nivolumab plus ipilimumab showed marked efficacy in patients with recurrent malignant pleural mesothelioma. The safety profile was consistent with known data on the combination regimen. Our results warrant further investigation of this combination in a phase 3 trial. FUNDING Bristol-Myers Squibb.
This paper references
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1016/j.jtho.2018.05.038
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
J. Quispel-Janssen (2018)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1200/JCO.2016.34.15_SUPPL.8503
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
R. Hassan (2016)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1007/s00280-018-3527-6
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
D. Waterhouse (2018)
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
10.1007/s10147-018-1305-4
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
S. Omori (2018)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1016/j.jtho.2018.08.2024
Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus.
C. J. de Gooijer (2018)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1016/j.jtho.2018.08.007
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y. Metaxas (2018)
10.1097/JTO.0b013e318208c83d
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
10.1016/0197-2456(89)90015-9
Optimal two-stage designs for phase II clinical trials.
R. Simon (1989)
10.1016/j.jtho.2017.02.013
The Immune Microenvironment, Genome‐wide Copy Number Aberrations, and Survival in Mesothelioma
B. Thapa (2017)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1007/s00262-017-2075-y
Safety of shortened infusion times for combined ipilimumab and nivolumab
M. Gassenmaier (2017)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.1158/2326-6066.CIR-16-0171
Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
M. Awad (2016)
10.1016/S2213-2600(18)30151-6
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
L. Calabrò (2018)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1371/journal.pone.0161779
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark Selby (2016)
10.1371/journal.pone.0176822
Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis
Tiancheng Zhao (2017)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1080/2162402X.2016.1278330
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
K. Kiyotani (2017)
10.1093/annhyg/meq076
Epidemiology of malignant mesothelioma--an outline.
J. C. Mcdonald (2010)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)



This paper is referenced by
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.1016/j.intimp.2020.106481
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
F. Zhang (2020)
10.1183/2312508x.10024219
Mesothelioma: is chemotherapy alone a thing of the past?
A. Bibby (2020)
10.1186/s13046-019-1259-z
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte (2019)
Immunotherapy for mesothelioma: rationale and new approaches.
Joshua E Reuss (2020)
10.1002/cam4.2661
Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
Jingli Lu (2019)
10.3390/cancers11060831
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma
A. Catino (2019)
10.1016/J.ANNONC.2020.09.009
A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
S. Popat (2020)
10.1177/1758835920971421
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
H. Yang (2020)
10.3390/cancers12040915
Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
Fabio Nicolini (2020)
10.21037/tlcr.2020.01.16
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
10.3390/cancers12020361
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
C. Chiarucci (2020)
10.1158/1078-0432.CCR-19-1836
Nivo-lution in Mesothelioma
A. Mansfield (2019)
10.1080/14712598.2020.1703945
Nivolumab for the treatment of unresectable pleural mesothelioma
K. Hotta (2019)
10.1016/j.coi.2020.04.005
Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma.
S. Mutsaers (2020)
10.3389/fonc.2020.00777
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
Robert A. Belderbos (2020)
10.1016/j.ctrv.2020.102101
Is DNA repair a potential target for effective therapies against malignant mesothelioma?
I. Fuso Nerini (2020)
10.3389/fonc.2020.00388
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
C. Blanquart (2020)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.1136/jitc-2019-000461
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
K. Hotta (2020)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.3389/fonc.2020.00343
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
L. Cantini (2020)
10.1016/j.lungcan.2019.12.018
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
10.1007/s12094-019-02275-9
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
S. Cedres (2020)
10.1016/j.jtho.2019.08.2506
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
A. Nicholson (2019)
10.21037/tlcr.2019.11.23
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
S. Gray (2020)
10.1016/j.lungcan.2020.05.023
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
K. Otsuka (2020)
10.1371/journal.pone.0229299
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma
J. Lim (2020)
10.5603/ARM.2019.0051
Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.
M. Sayan (2019)
10.3389/fphar.2020.00040
Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
Y. Yang (2020)
10.1016/j.cllc.2020.10.005
A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
R. Shah (2020)
10.1038/s41379-019-0364-z
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
S. Muller (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar